FirstWord

The Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) programme aims to create an automated manufacturing network that has the "speed, scale and reach" to create therapies on-demand.

SIM0660, which combines a CD3-engaging arm with binding domains targeting CD79a and CD19, is designed to treat B-cell–mediated diseases broadly.

Oral TYK2 inhibitor envudeucitinib missed its primary endpoint in the overall trial population, but a subgroup of patients with a high interferon gene signature had "robust" responses to treatment.

AstraZeneca and Daiichi Sankyo's Enhertu plus Roche's Perjeta extended median progression-free survival beyond three years in the DESTINY-Breast09 trial.

The SANOVO results for Tagrisso plus Orpathys bolster the case for tackling MET-driven resistance early.

Full results from AstraZeneca and Ionis' RNA silencer Wainua (eplontersen) in the Phase III CARDIO-TTRansform trial presented at the European Society of Cardiology (ESC) annual meeting offered a deep dive for all those seeking to understand what went wrong. FirstWord is polling physicians for their

FirstWord will host an expert call with a KOL in the coming days to discuss what readthrough the Librexia ACS results could have to other ongoing trials of milvexian in atrial fibrillation and secondary stroke prevention, and to competing factor XIa inhibitors in the clinic.

BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and developmen...

ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)-- Drug Farm today announced positive ophthalmologic and systemic findings from its international Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibito...

Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027KT-621 BREADTH Phase 2b asthma trial ongoing,...